Hizentra
Hizentra is an Immune Globulin Subcutaneous (Human) 20% Liquid indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older, and for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
Dosage by Body Weight
For subcutaneous infusion only. Dosage must be individualized based on the patient's clinical response, previous IgG trough levels, and body weight. The weekly dose for CIDP is 0.2 g/kg to 0.4 g/kg body weight, administered in weekly or biweekly regimens.
- Body Weight
- Below 5 kg
- Dose
- Not routine / Individually calculated
- Frequency
- Use only if prescribed
- Tracking Notes
- Safety and efficacy in pediatric patients below 2 years of age have not been established. Dose must be strictly calculated based on body weight (e.g., 0.2 to 0.4 g/kg) by a healthcare provider.
- Body Weight
- 5-7 kg
- Dose
- 1.0 g to 2.8 g weekly
- Frequency
- Once weekly (or divided into multiple sessions)
- Tracking Notes
- Calculated based on standard weekly dosing of 0.2 g/kg to 0.4 g/kg. Actual dose must be customized by the prescribing physician.
- Body Weight
- 8-10 kg
- Dose
- 1.6 g to 4.0 g weekly
- Frequency
- Once weekly (or divided into multiple sessions)
- Tracking Notes
- Calculated based on standard weekly dosing of 0.2 g/kg to 0.4 g/kg. Monitor infusion site and rate closely.
- Body Weight
- 11-15 kg
- Dose
- 2.2 g to 6.0 g weekly
- Frequency
- Once weekly (or divided into multiple sessions)
- Tracking Notes
- Calculated based on standard weekly dosing of 0.2 g/kg to 0.4 g/kg. Adjustments may be made based on serum IgG trough levels.
- Body Weight
- 16-20 kg
- Dose
- 3.2 g to 8.0 g weekly
- Frequency
- Once weekly (or divided into multiple sessions)
- Tracking Notes
- Calculated based on standard weekly dosing of 0.2 g/kg to 0.4 g/kg. Infusion volume per site should not exceed 25 mL for pediatric patients.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not routine / Individually calculated | Use only if prescribed | Safety and efficacy in pediatric patients below 2 years of age have not been established. Dose must be strictly calculated based on body weight (e.g., 0.2 to 0.4 g/kg) by a healthcare provider. |
| 5-7 kg | 1.0 g to 2.8 g weekly | Once weekly (or divided into multiple sessions) | Calculated based on standard weekly dosing of 0.2 g/kg to 0.4 g/kg. Actual dose must be customized by the prescribing physician. |
| 8-10 kg | 1.6 g to 4.0 g weekly | Once weekly (or divided into multiple sessions) | Calculated based on standard weekly dosing of 0.2 g/kg to 0.4 g/kg. Monitor infusion site and rate closely. |
| 11-15 kg | 2.2 g to 6.0 g weekly | Once weekly (or divided into multiple sessions) | Calculated based on standard weekly dosing of 0.2 g/kg to 0.4 g/kg. Adjustments may be made based on serum IgG trough levels. |
| 16-20 kg | 3.2 g to 8.0 g weekly | Once weekly (or divided into multiple sessions) | Calculated based on standard weekly dosing of 0.2 g/kg to 0.4 g/kg. Infusion volume per site should not exceed 25 mL for pediatric patients. |
Formulation
Purpose
Used to treat Primary Immunodeficiency (PI) in patients 2 years of age and older, and to treat adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to prevent relapse of neuromuscular disability.
Generic Name
Immune Globulin Subcutaneous (Human), 20% LiquidScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.